TMCI Investors Have the Opportunity to Lead the Treace Medical Securities Fraud Lawsuit with Faruqi & Faruqi, LLP
1. Faruqi & Faruqi investigates claims against Treace Medical (TMCI). 2. Allegations involve misleading statements affecting demand for Lapiplasty product. 3. TMCI lowered 2024 revenue guidance due to increased competition. 4. Stock price dropped nearly 63% after revenue guidance downgrade. 5. Investors face June 10, 2025 deadline to seek lead plaintiff role.